Oxaliplatin Sandoz (Oxaliplatin)

Oxaliplatin Sandoz is a platinum‑based chemotherapeutic agent used in the treatment of cancers that involve the gastrointestinal tract.

• Colorectal cancer: improves survival when combined with fluoropyrimidine chemotherapy.
• Gastric cancer: used as part of combination regimens for advanced disease.
• Pancreatic cancer: contributes to tumor response in selected combination protocols.
• Esophageal cancer: employed in multi‑drug regimens for locally advanced cases.
• Small‑cell lung cancer: occasionally incorporated into experimental combination therapies.
• Peritoneal carcinomatosis: used in intraperitoneal chemotherapy approaches.

• Oxaliplatin forms reactive platinum‑DNA adducts that disrupt DNA replication and transcription, leading to cell‑cycle arrest and apoptosis. The drug preferentially forms intra‑strand cross‑links, interfering with tumor cell repair mechanisms and enhancing cytotoxicity when combined with fluoropyrimidines.

Oxaliplatin may cause a range of adverse reactions, from mild to severe, that require monitoring during treatment.

Common Side Effects

• Nausea and vomiting: frequently reported during infusion.
• Peripheral neuropathy: tingling or numbness, often dose‑related.
• Diarrhoea: may be mild to moderate in severity.
• Fatigue: generalised tiredness experienced by many patients.
• Thrombocytopenia: reduced platelet count observed in blood tests.
• Elevated liver enzymes: mild transaminase increases.

Serious or Rare Side Effects

• Severe hypersensitivity reactions: including anaphylaxis.
• Acute neurotoxicity: sudden onset of muscle cramps or spasms.
• Persistent peripheral neuropathy: long‑lasting sensory deficits.
• Bone marrow suppression: leading to neutropenia or anaemia.
• Renal impairment: decreased kidney function in susceptible individuals.
• Cardiac arrhythmias: irregular heart rhythms observed in rare cases.

When using Oxaliplatin Sandoz, clinicians should consider several safety measures to minimise risks.

• Renal function: assess baseline creatinine and monitor regularly.
• Neuropathy risk: evaluate pre‑existing peripheral neuropathy before each cycle.
• Hematologic monitoring: perform complete blood counts prior to infusion.
• Hepatic function: check liver enzymes and bilirubin levels.
• Pregnancy and lactation: avoid use unless benefits clearly outweigh risks.
• Storage: Store below 25°C: keep in the original container, protect from light and moisture.

Oxaliplatin can interact with other medicines, affecting its safety and efficacy.

Major Interactions (Avoid)

• Nephrotoxic agents: concurrent use with high‑dose cisplatin or aminoglycosides may worsen kidney injury.
• Anticoagulants: increased bleeding risk when combined with warfarin or direct oral anticoagulants.
• High‑dose vitamin C: may reduce platinum‑DNA binding efficacy.

Moderate Interactions (Monitor Closely)

• Fluoropyrimidines (5‑FU, capecitabine): enhanced neurotoxicity when given together.
• Antiemetics (serotonin antagonists): may require dose adjustment for optimal control.
• CYP3A4 inhibitors: potential alteration of drug clearance, requiring monitoring.